BVS Bioventus

Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET).

The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025.

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit , and follow the Company on and . Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:

Dave Crawford

919-474-6787



EN
07/01/2025

Underlying

BVSBioventus

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioventus

 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Confere...

Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About BioventusBioventus delivers clinical...

January 7, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Completes Divestiture of its Advanced Rehabilitation Busines...

Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and execu...

January 2, 2025 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Reports Third Quarter Financial Results

Bioventus Reports Third Quarter Financial Results Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared to Previous Year DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024. “We delivered strong financial results in the third quarter, including double-di...

November 5, 2024 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Result...

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Cal...

October 29, 2024 1 EN
 PRESS RELEASE
Free
BVS BIOVENTUS

Bioventus Announces Divestiture of its Advanced Rehabilitation Busines...

Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners DURHAM, N.C., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Advanced Rehabilitation business of its subsidiary, Bioness, to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction includes a total cash consideration of $45 million, including $25 ...

October 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch